Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab to prevent in-stent restenosis after PCI for coronary CTO
ChiCTR2300076771Phase 4Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in Chronic coronary occlusion (CTO) and coronary arteriosclerosis (2 arms), sponsored by Fuwai Hospital. Primary endpoint: In-stent neointimal loading percentage. Started Sep 2021; status: recruiting.
02
Drugs
evolocumab
03
Conditions
Chronic coronary occlusion (CTO)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300076771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076771.